Vivozon Pharmaceutical Co Ltd

Vivozon's capital structure shows a debt-to-equity ratio of 0.38, indicating a relatively conservative leverage position compared to the industry median of 0.52. The company's liquidity position is concerning, with a current ratio of 0.63 and negative free cash flow of -4.0 billion KRW, suggesting short-term liquidity constraints. The price-to-book ratio of 1.52 implies the market values the company at a premium to its book value, but this is not supported by positive returns on equity or assets.

Profitability metrics reveal significant underperformance. The company reported a net loss of 986.9 million KRW and negative ROE of -0.96%, far below the industry median ROE of 12.3%. Gross margin of 49.9% is in line with the industry median, but operating margin of 3.6% is below the 7.1% median for pharmaceutical firms, indicating operational inefficiencies.

Geographic and segment exposure is not disclosed in the available data, but the company's revenue concentration in a single country (South Korea) and limited product portfolio suggest high business risk. The lack of segment reporting prevents a detailed analysis of revenue diversification.

Growth trajectory is mixed. While the company's FY revenue of 19.9 billion KRW is 43% above the analyst estimate of 4.6 billion KRW, the net loss and negative cash flows indicate financial distress. The outlook for the next fiscal year is uncertain, with no clear guidance on margin expansion or R&D progress.

Risk factors include liquidity constraints, with negative free cash flow and a current ratio below 1. The risk assessment flags net cash as negative after subtracting total debt, and the company has low dilution risk with no near-term pressure from share issuance. However, the negative operating cash flow of -218.7 million KRW raises concerns about the company's ability to fund operations without external financing.

Recent events include the latest financial filing showing a significant revenue beat but a widening net loss. No recent earnings call transcripts or regulatory filings provide additional context on strategic initiatives or financial remediation plans.

Revenue grew 22.8% year-over-year to 87.6 billion KRW, demonstrating strong top-line expansion momentum.

Gross profit increased significantly to 45.4 billion KRW, indicating improved product pricing or cost efficiency.

Long-term debt decreased to 36.5 billion KRW, suggesting active deleveraging and improved balance sheet health.

The debt-to-equity ratio of 0.38 is below the pharmaceutical cohort median of 0.18, indicating conservative leverage.

Operating income turned positive at 1.8 billion KRW, marking a shift from previous operating losses.

The company faces high credit risk, posing potential challenges for financing and operational stability.

Net margin of -4.97% trails the pharmaceutical cohort median of 3.9%, reflecting inferior profitability.

Cash conversion ratio of 0.22 is in the bottom quartile, indicating poor efficiency in generating cash.

Revenue KRW 17.80B, −14,7% YoY; Operating income −878,1% YoY.

• ▍Revenue KRW 17.80B, −14,7% YoY
• ▍Operating income −878,1% YoY
• ▍Net income −708,5% YoY
• ▍Free cash flow −197,3% YoY
• ▍Net margin -23.7%

Revenue KRW 59.34B, −32,3% YoY; Operating income −1 429,2% YoY.

• ▍Revenue KRW 59.34B, −32,3% YoY
• ▍Operating income −1 429,2% YoY
• ▍Net income −224,8% YoY
• ▍Free cash flow −70,7% YoY
• ▍Net margin -54.6%